Diagnostic Value of Immunohistochemical Staining of GP73, GPC3, DCP, CD34, CD31, and Reticulin Staining in Hepatocellular Carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 9, 2013, Pages 639-648

  Yao, Shuzhe ^a   Zhang, Jianping ^a   Chen, Haiyan ^a   Sheng, Yan ^a   Zhang, Xiaoying ^a   Liu, Zhiyan ^a   Zhang, Cuijuan ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD34; GP73; GPC3; hepatocellular carcinoma; immunohistochemistry

Indexed keywords

CD31 ANTIGEN; DECARBOXYPROTHROMBIN; GLYPICAN 3; GOLGI PROTEIN 73; MEMBRANE PROTEIN; RETICULIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD34 ANTIGEN; GLYPICAN; GOLM1 PROTEIN, HUMAN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; CD34; GP73; GPC3; LIVER; LIVER TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; STAINING;

CD34; GP73; GPC3; HEPATOCELLULAR CARCINOMA; IMMUNOHISTOCHEMISTRY;

ANTIGENS, CD31; ANTIGENS, CD34; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; PROTEIN PRECURSORS; PROTHROMBIN; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 84886785792     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413492771     Document Type: Article

References (55)

1. Akkiz H,Bayram S,Bekar A,Akgollu E,Uskudar O,Sandikci M.No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population: a case-control study.Gene. 2011;486:104-109.
2. Bachert C,Fimmel C,Linstedt AD.Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma.Traffic. 2007;8:1415-1423.
3. Baumhoer D,Tornillo L,Stadlmann S,Roncalli M,Diamantis EK,Terracciano LM.Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.Am J Clin Pathol. 2008;129:899-906.
4. Beneduce L,Pesce G,Gallotta A,Zampieri F,Biasiolo A,Tono N,Boscato N,Gatta A,Pontisso P,Fassina G.Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.Eur J Clin Invest. 2008;38:571-577.
5. Block TM,Comunale MA,Lowman M,Steel LF,Romano PR,Fimmel C,Tennant BC,London WT,Evans AA,Blumberg BS, et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.Proc Natl Acad Sci U S A. 2005;102:779-784.
6. Capurro M,Wanless IR,Sherman M,Deboer G,Shi W,Miyoshi E,Filmus J.Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.Gastroenterology. 2003;125:89-97.
7. Coston WM,Loera S,Lau SK,Ishizawa S,Jiang Z,Wu CL,Yen Y,Weiss LM,Chu PG.Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry.Am J Surg Pathol. 2008;32:433-444.
8. Couvelard A,Scoazec JY,Feldmann G.Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver.Am J Pathol. 1993;143:738-752.
9. de Boer WB,Segal A,Frost FA,Sterrett GF.Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?.Cancer. 2000;90:273-278.
10. El-Serag HB,Mallat DB,Rabeneck L.Management of the single liver nodule in a cirrhotic patient: a decision analysis model.J Clin Gastroenterol. 2005;39:152-159.
11. El-Serag HB,Rudolph KL.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology. 2007;132:2557-2576.
12. Farazi PA,DePinho RA.Hepatocellular carcinoma pathogenesis: from genes to environment.Nat Rev Cancer. 2006;6:674-687.
13. Farinati F,Marino D,De Giorgio M,Baldan A,Cantarini M,Cursaro C,Rapaccini G,Del Poggio P,Di Nolfo MA,Benvegnu L, et al.Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?.Am J Gastroenterol. 2006;101:524-532.
14. Filmus J,Capurro M,Rast J.Glypicans.Genome Biol. 2008;9:224.
15. Frachon S,Gouysse G,Dumortier J,Couvelard A,Nejjari M,Mion F,Berger F,Paliard P,Boillot O,Scoazec JY.Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study.J Hepatol. 2001;34:850-857.
16. Gomori G.Concerning methods of tissue staining.Am J Clin Pathol. 1947;17:972.
17. Heukamp LC,Fischer HP,Schirmacher P,Chen X,Breuhahn K,Nicolay C,Buttner R,Gutgemann I.Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions.Histopathology. 2006;49:242-247.
18. Inagaki Y,Tang W,Makuuchi M,Hasegawa K,Sugawara Y,Kokudo N.Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin.Liver Int. 2011;31:22-35.
19. Terminology of nodular hepatocellular lesions.Hepatology. 1995;22:983-993.
20. Jia HL,Ye QH,Qin LX,Budhu A,Forgues M,Chen Y,Liu YK,Sun HC,Wang L,Lu HZ, et al.Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.Clin Cancer Res. 2007;13:1133-1139.
21. Jin Y,Yu Q,Zhou D,Chen L,Huang X,Xu G,Huang J,Gao X,Gao Y,Shen L.The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population.Genet Test Mol Biomarkers. 2012;16:330-334.
22. Jing X,Piao YF,Liu Y,Gao PJ.Beta2-GPI: a novel factor in the development of hepatocellular carcinoma.J Cancer Res Clin Oncol. 2010;136:1671-1680.
23. Kandil DH,Cooper K.Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.Adv Anat Pathol. 2009;16:125-129.
24. Kladney RD,Cui X,Bulla GA,Brunt EM,Fimmel CJ.Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease.Hepatology. 2002;35:1431-1440.
25. Lai JP,Sandhu DS,Yu C,Han T,Moser CD,Jackson KK,Guerrero RB,Aderca I,Isomoto H,Garrity-Park MM, et al.Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.Hepatology. 2008;47:1211-1222.
26. Li L,Li J,Hao C,Zhang C,Mu K,Wang Y,Zhang T.Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: the expression pattern of CD99 is highly unique.Cancer Lett. 2011;310:9-14.
27. Li WC,Ye SL,Sun RX,Liu YK,Tang ZY,Kim Y,Karras JG,Zhang H.Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.Clin Cancer Res. 2006;12:7140-7148.
28. Libbrecht L,Severi T,Cassiman D,Vander Borght S,Pirenne J,Nevens F,Verslype C,van Pelt J,Roskams T.Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.Am J Surg Pathol. 2006;30:1405-1411.
29. Liu X,Wan X,Li Z,Lin C,Zhan Y,Lu X.Golgi protein 73(GP73), a useful serum marker in liver diseases.Clin Chem Lab Med. 2011;49:1311-1316.
30. Lok AS,Sterling RK,Everhart JE,Wright EC,Hoefs JC,Di Bisceglie AM,Morgan TR,Kim HY,Lee WM,Bonkovsky HL, et al.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Gastroenterology. 2010;138:493-502.
31. Mao Y,Yang H,Xu H,Lu X,Sang X,Du S,Zhao H,Chen W,Xu Y,Chi T, et al.Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.Gut. 2010;59:1687-1693.
32. Marrero JA,Romano PR,Nikolaeva O,Steel L,Mehta A,Fimmel CJ,Comunale MA,D'Amelio A,Lok AS,Block TM.GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.J Hepatol. 2005;43:1007-1012.
33. Marrero JA,Su GL,Wei W,Emick D,Conjeevaram HS,Fontana RJ,Lok AS.Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients.Hepatology. 2003;37:1114-1121.
34. Murthy SS,Shen T,De Rienzo A,Lee WC,Ferriola PC,Jhanwar SC,Mossman BT,Filmus J,Testa JR.Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma.Oncogene. 2000;19:410-416.
35. Ozkan H,Erdal H,Kocak E,Tutkak H,Karaeren Z,Yakut M,Koklu S.Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.J Clin Lab Anal. 2011;25:350-353.
36. Pusztaszeri MP,Seelentag W,Bosman FT.Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues.J Histochem Cytochem. 2006;54:385-395.
37. Riener MO,Stenner F,Liewen H,Soll C,Breitenstein S,Pestalozzi BC,Samaras P,Probst-Hensch N,Hellerbrand C,Mullhaupt B, et al.Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas.Hepatology. 2009;49:1602-1609.
38. Sato K,Mori M.Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.Curr Med Chem. 2011;18:4375-4388.
39. Scoazec JY,Feldmann G.The cell adhesion molecules of hepatic sinusoidal endothelial cells.J Hepatol. 1994;20:296-300.
40. Shafizadeh N,Ferrell LD,Kakar S.Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.Mod Pathol. 2008;21:1011-1018.
41. Sterling RK,Wright EC,Morgan TR,Seeff LB,Hoefs JC,Di Bisceglie AM,Dienstag JL,Lok AS.Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.Am J Gastroenterol. 2012;107:64-74.
42. Stigliano I,Puricelli L,Filmus J,Sogayar MC,Bal de Kier Joffe E,Peters MG.Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.Breast Cancer Res Treat. 2009;114:251-262.
43. Sun HC,Tang ZY,Li XM,Zhou YN,Sun BR,Ma ZC.Microvessel density of hepatocellular carcinoma: its relationship with prognosis.J Cancer Res Clin Oncol. 1999;125:419-426.
44. Suzuki M,Sugimoto K,Tanaka J,Tameda M,Inagaki Y,Kusagawa S,Nojiri K,Beppu T,Yoneda K,Yamamoto N, et al.Up-regulation of glypican-3 in human hepatocellular carcinoma.Anticancer Res. 2010;30:5055-5061.
45. Takeji S,Hirooka M,Koizumi Y,Tokumoto Y,Abe M,Ikeda Y,Nadano S,Hiasa Y,Onji M.Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma.J Gastroenterol Hepatol. 2013;28:671-677.
46. Tangkijvanich P,Chanmee T,Komtong S,Mahachai V,Wisedopas N,Pothacharoen P,Kongtawelert P.Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.J Gastroenterol Hepatol. 2010;25:129-137.
47. Tatrai P,Somoracz A,Batmunkh E,Schirmacher P,Kiss A,Schaff Z,Nagy P,Kovalszky I.Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.Am J Surg Pathol. 2009;33:874-885.
48. Tian L,Wang Y,Xu D,Gui J,Jia X,Tong H,Wen X,Dong Z,Tian Y.Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases.Int J Cancer. 2011;129:1923-1931.
49. Viviano BL,Silverstein L,Pflederer C,Paine-Saunders S,Mills K,Saunders S.Altered hematopoiesis in glypican-3-deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification.Dev Biol. 2005;282:152-162.
50. Wang XY,Degos F,Dubois S,Tessiore S,Allegretta M,Guttmann RD,Jothy S,Belghiti J,Bedossa P,Paradis V.Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.Hum Pathol. 2006;37:1435-1441.
51. Yamamoto K,Imamura H,Matsuyama Y,Hasegawa K,Beck Y,Sugawara Y,Makuuchi M,Kokudo N.Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.Ann Surg Oncol. 2009;16:2795-2804.
52. Yamamoto K,Imamura H,Matsuyama Y,Kume Y,Ikeda H,Norman GL,Shums Z,Aoki T,Hasegawa K,Beck Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.J Gastroenterol. 2010;45:1272-1282.
53. Yan D,He Q,Chen Y,Wang L,Zhang X.Detection of alpha-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.J Clin Lab Anal. 2011;25:113-117.
54. Zhu ZW,Friess H,Wang L,Abou-Shady M,Zimmermann A,Lander AD,Korc M,Kleeff J,Buchler MW.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.Gut. 2001;48:558-564.
55. Zynger DL,McCallum JC,Luan C,Chou PM,Yang XJ.Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns.Histopathology. 2010;56:750-757.